Allan S Jaffe

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/7747364/allan-s-jaffe-publications-by-year.pdf
Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

293 papers	29,174 citations	74 h-index	167 g-index
340 ext. papers	34,660 ext. citations	5.7 avg, IF	7.13 L-index

#	Paper	IF	Citations
293	Assessing the Accuracy of Estimated Lipoprotein(a) Cholesterol and Lipoprotein(a)-Free Low-Density Lipoprotein Cholesterol.. *Journal of the American Heart Association*, **2022**, e023136	6	1
292	Sex disparities in management and outcomes of cardiac arrest complicating acute myocardial infarction in the United States.. *Resuscitation*, **2022**, 172, 92-100	4	2
291	Use and Prognostic Implications of Cardiac Troponin in COVID-19. *Cardiology Clinics*, **2022**,	2.5	1
290	Management and Outcomes of Acute Myocardial Infarction-Cardiogenic Shock in Uninsured Compared With Privately Insured Individuals.. *Circulation: Heart Failure*, **2022**, CIRCHEARTFAILURE121008991	7.6	0
289	Plasma Ceramide Levels Are Elevated in Patients With Early Coronary Atherosclerosis and Endothelial Dysfunction.. *Journal of the American Heart Association*, **2022**, e022852	6	0
288	Sex-Specific 99th Percentile URLs for Cardiac Troponin Assays-Their Time Has Come. *Clinical Chemistry*, **2021**, 67, 197-200	5.5	0
287	Biomarkers of coagulation and fibrinolysis in acute myocardial infarction: a joint position paper of the Association for Acute CardioVascular Care and the European Society of Cardiology Working Group on Thrombosis. *European Heart Journal: Acute Cardiovascular Care*, **2021**, 10, 343-355	4.3	4
286	Cardiogenic shock complicating non-ST-segment elevation myocardial infarction: An 18-year study. *American Heart Journal*, **2021**, 244, 54-65	4.9	0
285	High-Sensitivity Troponin T Testing for Pediatric Patients in the Emergency Department. *Pediatric Cardiology*, **2021**, 1	2.1	0
284	Reply: Applying High-Sensitivity Cardiac Troponin T. *Journal of the American College of Cardiology*, **2021**, 78, e149-e150	15.1	
283	Prediction of Death After Noncardiac Surgery: Potential Advantage of Using High-Sensitivity Troponin T as a Continuous Variable. *Journal of the American Heart Association*, **2021**, 10, e018008	6	1
282	Return-to-Play Guidelines for Athletes After COVID-19 Infection. *JAMA Cardiology*, **2021**, 6, 479	16.2	1
281	Racial Disparities in the Utilization and Outcomes of Temporary Mechanical Circulatory Support for Acute Myocardial Infarction-Cardiogenic Shock. *Journal of Clinical Medicine*, **2021**, 10,	5.1	2
280	High-Sensitivity Cardiac Troponin T for the Detection of Myocardial Injury and Risk Stratification in COVID-19. *Clinical Chemistry*, **2021**, 67, 1080-1089	5.5	7
279	Ceramide Scores Predict Cardiovascular Risk in the Community. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2021**, 41, 1558-1569	9.4	7
278	Using high sensitivity cardiac troponin values in patients with SARS-CoV-2 infection (COVID-19): The Padova experience. *Clinical Biochemistry*, **2021**, 90, 8-14	3.5	8
277	Prognostically relevant periprocedural myocardial injury and infarction associated with percutaneous coronary interventions: a Consensus Document of the ESC Working Group on Cellular Biology of the Heart and European Association of Percutaneous Cardiovascular Interventions (EAPCI). *European Heart Journal*, **2021**, 42, 2630-2642	9.5	13

276	Clinical Impact of High-Sensitivity Cardiac Troponin T Implementation in the´Community. *Journal of the American College of Cardiology*, **2021**, 77, 3160-3170	15.1	7
275	Biomarker Testing Considerations in the Evaluation and Management of Patients With Heart Failure: Perspectives From the International Federation of Clinical Chemistry and Laboratory Medicine Committee. *Journal of Cardiac Failure*, **2021**, 27, 1456-1461	3.3	0
274	Pre-analytical considerations in biomarker research: focus on cardiovascular disease. *Clinical Chemistry and Laboratory Medicine*, **2021**, 59, 1747-1760	5.9	1
273	Sex-specific cut-off values for soluble suppression of tumorigenicity 2 (ST2) biomarker increase its cardiovascular prognostic value in the community. *Biomarkers*, **2021**, 26, 639-646	2.6	0
272	Procedural myocardial injury, infarction and mortality in patients undergoing elective PCI: a pooled analysis of patient-level data. *European Heart Journal*, **2021**, 42, 323-334	9.5	21
271	ESC Study Group on Cardiac Biomarkers of the Association for Acute CardioVascular Care: A fond farewell at the retirement of CKMB. *European Heart Journal*, **2021**, 42, 2260-2264	9.5	12
270	Biomarker and Invasive Hemodynamic Assessment of Cardiac Damage Class in Aortic Stenosis. *Structural Heart*, **2021**, 5, 208-217	0.6	0
269	Getting Cardiac Troponin Right: Appraisal of the 2020 European Society of Cardiology Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation by the International Federation of Clinical Chemistry and Laboratory Medicine Committee on Clinical Applications of Cardiac Bio-Markers. *Clinical Chemistry*, **2021**, 67, 730-735	5.5	11
268	Cardiovascular biomarkers in patients with COVID-19. *European Heart Journal: Acute Cardiovascular Care*, **2021**, 10, 310-319	4.3	16
267	Analytical and Clinical Considerations in Implementing the Roche Elecsys Troponin T Gen 5 STAT Assay. *American Journal of Clinical Pathology*, **2021**, 156, 1121-1129	1.9	0
266	Influence of primary payer status on non-ST-segment elevation myocardial infarction: 18-year retrospective cohort national temporal trends, management and outcomes. *Annals of Translational Medicine*, **2021**, 9, 1075	3.2	1
265	The Elevated High-Sensitivity Cardiac Troponin T Pilot: Diagnoses and Outcomes. *Mayo Clinic Proceedings*, **2021**, 96, 2366-2375	6.4	1
264	Temporal Trends, Predictors, and Outcomes of Acute Ischemic Stroke in Acute Myocardial Infarction in the United States. *Journal of the American Heart Association*, **2021**, 10, e017693	6	8
263	Weekend Effect in the Management and Outcomes of Acute Myocardial Infarction in the United States, 2000-2016. *Mayo Clinic Proceedings Innovations, Quality & Outcomes*, **2020**, 4, 362-372	3.1	13
262	Ceramides improve atherosclerotic cardiovascular disease risk assessment beyond standard risk factors. *Clinica Chimica Acta*, **2020**, 511, 138-142	6.2	9
261	The Universal Definition of Myocardial Infarction: Present and Future. *Circulation*, **2020**, 141, 1434-1436	16.7	8
260	Myocardial injury in severe COVID-19 infection. *European Heart Journal*, **2020**, 41, 2080-2082	9.5	20
259	Implementing High-Sensitivity Cardiac Troponin T in a US Regional Healthcare System. *Circulation*, **2020**, 141, 1937-1939	16.7	4

258	Complications in Patients with Acute Myocardial Infarction Supported with Extracorporeal Membrane Oxygenation. *Journal of Clinical Medicine*, **2020**, 9,	5.1	20
257	Cardiac Troponin for Assessment of Myocardial Injury in COVID-19: JACC Review Topic of the Week. *Journal of the American College of Cardiology*, **2020**, 76, 1244-1258	15.1	174
256	Prognostic Value of N-Terminal Pro-form B-Type Natriuretic Peptide in Patients With Moderate Aortic Stenosis. *American Journal of Cardiology*, **2020**, 125, 1566-1570	3	4
255	Regional Variation in the Management and Outcomes of Acute Myocardial Infarction With Cardiogenic Shock in the United States. *Circulation: Heart Failure*, **2020**, 13, e006661	7.6	44
254	Natriuretic Peptides to Predict Short-Term Mortality in Patients With Sepsis: A Systematic Review and Meta-analysis. *Mayo Clinic Proceedings Innovations, Quality & Outcomes*, **2020**, 4, 50-64	3.1	16
253	Pulmonary artery catheter use in acute myocardial infarction-cardiogenic shock. *ESC Heart Failure*, **2020**, 7, 1234-1245	3.7	31
252	Influence of primary payer status on the management and outcomes of ST-segment elevation myocardial infarction in the United States. *PLoS ONE*, **2020**, 15, e0243810	3.7	3
251	Measuring the contribution of Lp(a) cholesterol towards LDL-C interpretation. *Clinical Biochemistry*, **2020**, 86, 45-51	3.5	5
250	Incidence, Trends, and Outcomes of Type 2 Myocardial Infarction in a Community Cohort. *Circulation*, **2020**, 141, 454-463	16.7	38
249	Early vs. delayed in-hospital cardiac arrest complicating ST-elevation myocardial infarction receiving primary percutaneous coronary intervention. *Resuscitation*, **2020**, 148, 242-250	4	32
248	Sex Disparities in the Management and Outcomes of Cardiogenic Shock Complicating Acute Myocardial Infarction in the Young. *Circulation: Heart Failure*, **2020**, 13, e007154	7.6	31
247	Atherosclerotic Cardiovascular Disease Risk Stratification Based on Measurements of Troponin and Coronary Artery Calcium. *Journal of the American College of Cardiology*, **2020**, 76, 357-370	15.1	17
246	Epidemiological Trends in the Timing of In-Hospital Death in Acute Myocardial Infarction-Cardiogenic Shock in the United States. *Journal of Clinical Medicine*, **2020**, 9,	5.1	10
245	Management and outcomes of uncomplicated ST-segment elevation myocardial infarction patients transferred after fibrinolytic therapy. *International Journal of Cardiology*, **2020**, 321, 54-60	3.2	5
244	Influence of Human Immunodeficiency Virus Infection on the Management and Outcomes of Acute Myocardial Infarction With Cardiogenic Shock. *Journal of Acquired Immune Deficiency Syndromes (1999)*, **2020**, 85, 331-339	3.1	1
243	99th Percentile Upper-Reference Limit of Cardiac Troponin and the Diagnosis of Acute Myocardial Infarction. *Clinical Chemistry*, **2020**, 66, 1167-1180	5.5	6
242	Intracranial Hemorrhage Complicating Acute Myocardial Infarction: An 18-Year National Study of Temporal Trends, Predictors, and Outcomes. *Journal of Clinical Medicine*, **2020**, 9,	5.1	2
241	Sex and Gender Disparities in the Management and Outcomes of Acute Myocardial Infarction-Cardiogenic Shock in Older Adults. *Mayo Clinic Proceedings*, **2020**, 95, 1916-1927	6.4	23

240	Biomarkers Enhance Discrimination and Prognosis of Type 2 Myocardial Infarction. *Circulation*, **2020**, 142, 1532-1544	16.7	14
239	Acute Myocardial Infarction Due to Fixed Coronary Artery Stenosis From Myocardial Bridging. *Cardiovascular Revascularization Medicine*, **2020**, 21, 91-93	1.6	3
238	ST-segment Elevation, Myocardial Injury, and Suspected or Confirmed COVID-19 Patients: Diagnostic and Treatment Uncertainties. *Mayo Clinic Proceedings*, **2020**, 95, 1107-1111	6.4	6
237	Temporal trends, predictors, and outcomes of acute kidney injury and hemodialysis use in acute myocardial infarction-related cardiogenic shock. *PLoS ONE*, **2019**, 14, e0222894	3.7	42
236	78-Year-Old Woman With Intermittent Chest Pain and Palpitations. *Mayo Clinic Proceedings*, **2019**, 94, e117-e121	6.4	
235	Letter by Sandoval et al Regarding Article, "Designing a Better Mousetrap: Reflections on the November 28, 2017, US Food and Drug Administration Meeting on Next-Generation "High-Sensitivity" Cardiac Troponin Assays to Diagnose Myocardial Infarction". *Circulation*, **2019**,	16.7	2
234	Temporal trends and outcomes of prolonged invasive mechanical ventilation and tracheostomy use in acute myocardial infarction with cardiogenic shock in the United States. *International Journal of Cardiology*, **2019**, 285, 6-10	3.2	49
233	Acute Noncardiac Organ Failure in Acute Myocardial Infarction With Cardiogenic Shock. *Journal of the American College of Cardiology*, **2019**, 73, 1781-1791	15.1	109
232	Type 2 Myocardial Infarction: JACC Review Topic of the Week. *Journal of the American College of Cardiology*, **2019**, 73, 1846-1860	15.1	113
231	Recommendations for Institutions Transitioning to High-Sensitivity Troponin Testing: JACC Scientific Expert Panel. *Journal of the American College of Cardiology*, **2019**, 73, 1059-1077	15.1	52
230	Fourth universal definition of myocardial infarction (2018).. *European Heart Journal*, **2019**, 40, 237-269	9.5	851
229	Educational Recommendations on Selected Analytical and Clinical Aspects of Natriuretic Peptides with a Focus on Heart Failure: A Report from the IFCC Committee on Clinical Applications of Cardiac Bio-Markers. *Clinical Chemistry*, **2019**, 65, 1221-1227	5.5	11
228	Changes in comorbidities, diagnoses, therapies and outcomes in a contemporary cardiac intensive care unit population. *American Heart Journal*, **2019**, 215, 12-19	4.9	55
227	Sex disparities in acute kidney injury complicating acute myocardial infarction with cardiogenic shock. *ESC Heart Failure*, **2019**, 6, 874-877	3.7	46
226	Acute respiratory failure and mechanical ventilation in cardiogenic shock complicating acute myocardial infarction in the USA, 2000-2014. *Annals of Intensive Care*, **2019**, 9, 96	8.9	49
225	Estimating short- and long-term reference change values and index of individuality for tests of platelet function. *Clinical Biochemistry*, **2019**, 74, 54-59	3.5	2
224	Clinical use of cardiac troponin for acute cardiac care and emerging opportunities in the outpatient setting. *Minerva Medica*, **2019**, 110, 139-156	2.2	4
223	Extracorporeal Membrane Oxygenation Use in Acute Myocardial Infarction in the United States, 2000 to 2014. *Circulation: Heart Failure*, **2019**, 12, e005929	7.6	54

222	Global Adoption of High-Sensitivity Cardiac Troponins and the Universal Definition of Myocardial Infarction. *Clinical Chemistry*, **2019**, 65, 484-489	5.5	38
221	High-Sensitivity Cardiac Troponin I Levels in Normal and Hypertensive Pregnancy. *American Journal of Medicine*, **2019**, 132, 362-366	2.4	12
220	Cardiac troponin and natriuretic peptide analytical interferences from hemolysis and biotin: educational aids from the IFCC Committee on Cardiac Biomarkers (IFCC C-CB). *Clinical Chemistry and Laboratory Medicine*, **2019**, 57, 633-640	5.9	27
219	Fourth Universal Definition of Myocardial Infarction: Will it change how we practice emergency medicine?. *Emergencias*, **2019**, 31, 55-57	0.9	2
218	The prognostic impact of periprocedural myocardial infarction and injury. *European Heart Journal*, **2018**, 39, 1110-1112	9.5	18
217	Clinical Laboratory Practice Recommendations for the Use of Cardiac Troponin in Acute Coronary Syndrome: Expert Opinion from the Academy of the American Association for Clinical Chemistry and the Task Force on Clinical Applications of Cardiac Bio-Markers of the International Federation of Clinical Chemistry and Laboratory Medicine. *Clinical Chemistry*, **2018**, 64, 645-655	5.5	211
216	Reply to letter by Trupp et al. *Clinical Biochemistry*, **2018**, 52, 174	3.5	0
215	Comparing analytical outliers and the percent of emergency department patients with results above the 99th percentile upper reference limit for 2 conventional and one high sensitivity troponin assay. *Clinical Biochemistry*, **2018**, 53, 104-109	3.5	7
214	Clarifying the Proper Definitions for Type 2 Myocardial Infarction. *Journal of the American College of Cardiology*, **2018**, 71, 1291	15.1	4
213	What to do when you question cardiac troponin values. *European Heart Journal: Acute Cardiovascular Care*, **2018**, 7, 577-586	4.3	43
212	Improving the Specificity of Cardiac Biomarkers-The Early Development of Cardiac Troponin I (cTnI) Assays. *Clinical Chemistry*, **2018**, 64, 609-610	5.5	
211	Prevalence of biotin supplement usage in outpatients and plasma biotin concentrations in patients presenting to the emergency department. *Clinical Biochemistry*, **2018**, 60, 11-16	3.5	46
210	Possible mechanisms behind cardiac troponin elevations. *Biomarkers*, **2018**, 23, 725-734	2.6	56
209	Comparison of high-sensitivity cardiac troponin I and T for the prediction of cardiac complications after non-cardiac surgery. *American Heart Journal*, **2018**, 203, 67-73	4.9	14
208	Fourth Universal Definition of Myocardial Infarction (2018). *Journal of the American College of Cardiology*, **2018**, 72, 2231-2264	15.1	1179
207	Fourth Universal Definition of Myocardial Infarction (2018). *Circulation*, **2018**, 138, e618-e651	16.7	865
206	Fourth Universal Definition of Myocardial Infarction (2018). *Global Heart*, **2018**, 13, 305-338	2.9	124
205	Plasma Ceramides. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2018**, 38, 1933-1939	9.4	97

204	ICare-ACS (Improving Care Processes for Patients With Suspected Acute Coronary Syndrome): A Study of Cross-System Implementation of a National Clinical Pathway. *Circulation*, **2018**, 137, 354-363	16.7	24
203	Analytical performance of an immunoassay to measure proenkephalin. *Clinical Biochemistry*, **2018**, 58, 72-77	3.5	16
202	Detectable High-Sensitivity Cardiac Troponin within the Population Reference Interval Conveys High 5-Year Cardiovascular Risk: An Observational Study. *Clinical Chemistry*, **2018**, 64, 1044-1053	5.5	23
201	High-Sensitivity Troponin in Patients With Coronary Artery Endothelial Dysfunction. *Journal of Invasive Cardiology*, **2018**, 30, 406-410	0.7	6
200	Does cardiac rhythm monitoring in patients with elevated troponin levels lead to changes in management?. *European Heart Journal: Acute Cardiovascular Care*, **2017**, 6, 545-552	4.3	2
199	Rapid rule out of acute myocardial infarction: novel biomarker-based strategies. *European Heart Journal: Acute Cardiovascular Care*, **2017**, 6, 218-222	4.3	46
198	Improving Prediction of Postoperative Myocardial Infarction With High-Sensitivity Cardiac Troponin T and NT-proBNP. *Anesthesia and Analgesia*, **2017**, 124, 398-405	3.9	36
197	Effect of Repeat Measurements of High-Sensitivity Cardiac Troponin on the Same Sample Using the European Society of Cardiology 0-Hour/1-Hour or 2-Hour Algorithms for Early Rule-Out and Rule-In for Myocardial Infarction. *Clinical Chemistry*, **2017**, 63, 1163-1165	5.5	19
196	Lipid Biomarkers for Risk Assessment in Acute Coronary Syndromes. *Current Cardiology Reports*, **2017**, 19, 48	4.2	9
195	Association of Postoperative High-Sensitivity Troponin Levels With Myocardial Injury and 30-Day Mortality Among Patients Undergoing Noncardiac Surgery. *JAMA - Journal of the American Medical Association*, **2017**, 317, 1642-1651	27.4	320
194	Rapid Rule-out of Acute Myocardial Infarction With a Single High-Sensitivity Cardiac Troponin T Measurement Below the Limit of Detection: A Collaborative Meta-analysis. *Annals of Internal Medicine*, **2017**, 166, 715-724	8	163
193	In Reply. *Clinical Chemistry*, **2017**, 63, 1167-1170	5.5	6
192	Using Biomarkers to Guide Heart Failure Therapy. *Clinical Chemistry*, **2017**, 63, 954-957	5.5	6
191	Biological variability of lipoprotein-associated phospholipase A activity in healthy individuals. *Clinical Biochemistry*, **2017**, 50, 347-349	3.5	3
190	Use of troponin assay 99th percentile as the decision level for myocardial infarction diagnosis. *American Heart Journal*, **2017**, 190, 135-139	4.9	21
189	Prognostic Value of Soluble ST2 After Myocardial Infarction: A Community Perspective. *American Journal of Medicine*, **2017**, 130, 1112.e9-1112.e15	2.4	50
188	Natriuretic Peptides and Analytical Barriers. *Clinical Chemistry*, **2017**, 63, 50-58	5.5	25
187	Cardiac Troponin Assays: Guide to Understanding Analytical Characteristics and Their Impact on Clinical Care. *Clinical Chemistry*, **2017**, 63, 73-81	5.5	202

186	Best Practices for Monitoring Cardiac Troponin in Detecting Myocardial Injury. *Clinical Chemistry*, **2017**, 63, 37-44	5.5	7
185	Specificity of B-Type Natriuretic Peptide Assays: Cross-Reactivity with Different BNP, NT-proBNP, and proBNP Peptides. *Clinical Chemistry*, **2017**, 63, 351-358	5.5	45
184	Commentary. *Clinical Chemistry*, **2017**, 63, 48-49	5.5	
183	Using High-Sensitivity Cardiac Troponin T for Acute Cardiac Care. *American Journal of Medicine*, **2017**, 130, 1358-1365.e1	2.4	26
182	High-Sensitivity Cardiac Troponin for the Diagnosis of Patients with Acute Coronary Syndromes. *Current Cardiology Reports*, **2017**, 19, 92	4.2	23
181	Renal Dysfunction: How to Think About That in Acute Coronary Syndromes. *Current Cardiology Reports*, **2017**, 19, 91	4.2	1
180	Sex-specific 99th percentiles derived from the AACC Universal Sample Bank for the Roche Gen 5 cTnT assay: Comorbidities and statistical methods influence derivation of reference limits. *Clinical Biochemistry*, **2017**, 50, 1073-1077	3.5	24
179	High-Sensitivity Cardiac Troponin T Improves the Diagnosis of Perioperative MI. *Anesthesia and Analgesia*, **2017**, 125, 1455-1462	3.9	15
178	Eliminating Creatine Kinase-Myocardial Band Testing in Suspected Acute Coronary Syndrome: A Value-Based Quality Improvement. *JAMA Internal Medicine*, **2017**, 177, 1508-1512	11.5	23
177	Contemporary Risk Stratification After Myocardial Infarction in the Community: Performance of Scores and Incremental Value of Soluble Suppression of Tumorigenicity-2. *Journal of the American Heart Association*, **2017**, 6,	6	10
176	Evaluating the atherogenic burden of individuals with a Friedewald-estimated low-density lipoprotein cholesterol . *Journal of Clinical Lipidology*, **2017**, 11, 1065-1072	4.9	29
175	Prognostic Value of Serial Measurements of Soluble Suppression of Tumorigenicity 2 and Galectin-3 in Ambulatory Patients With Chronic Heart Failure. *Journal of Cardiac Failure*, **2016**, 22, 249-55	3.3	25
174	Ultra-Sensitive Copeptin and Cardiac Troponin in Diagnosing Non-ST-Segment Elevation Acute Coronary Syndromes--The COPACS Study. *American Journal of Medicine*, **2016**, 129, 105-14	2.4	4
173	Biomarker-based risk prediction in the community. *European Journal of Heart Failure*, **2016**, 18, 1342-1350	12.3	16
172	Elevation of cardiac troponin T in patients with amyotrophic lateral sclerosis. *Acta Neurologica Belgica*, **2016**, 116, 557-564	1.5	4
171	Advantages of the lipoprotein-associated phospholipase A2 activity assay. *Clinical Biochemistry*, **2016**, 49, 172-5	3.5	21
170	Can Natriuretic Peptides be Used to Guide Therapy?. *Electronic Journal of the International Federation of Clinical Chemistry and Laboratory Medicine*, **2016**, 27, 208-16	2.4	8
169	High Sensitivity Cardiac Troponin Assays - How to Implement them Successfully. *Electronic Journal of the International Federation of Clinical Chemistry and Laboratory Medicine*, **2016**, 27, 217-23	2.4	6

168	Should the 1h algorithm for rule in and rule out of acute myocardial infarction be used universally?. *European Heart Journal*, **2016**, 37, 3316-3323	9.5	21
167	From statistical significance to clinical relevance: A simple algorithm to integrate brain natriuretic peptide and the Seattle Heart Failure Model for risk stratification in heart failure. *Journal of Heart and Lung Transplantation*, **2016**, 35, 714-21	5.8	9
166	Implementation of Clinical Decision Support Rules to Reduce Repeat Measurement of Serum Ionized Calcium, Serum Magnesium, and N-Terminal Pro-B-Type Natriuretic Peptide in Intensive Care Unit Inpatients. *Clinical Chemistry*, **2016**, 62, 824-30	5.5	17
165	Effectiveness of EDACS Versus ADAPT Accelerated Diagnostic Pathways for Chest Pain: A Pragmatic Randomized Controlled Trial Embedded Within Practice. *Annals of Emergency Medicine*, **2016**, 68, 93-102.e1	2.1	84
164	Biomarkers in heart failure: the importance of inconvenient details. *ESC Heart Failure*, **2016**, 3, 3-10	3.7	14
163	Sensitive troponin assay and the classification of myocardial infarction. *American Journal of Medicine*, **2015**, 128, 493-501.e3	2.4	102
162	Soluble ST2--analytical considerations. *American Journal of Cardiology*, **2015**, 115, 8B-21B	3	67
161	Acute coronary syndromes in the community. *Mayo Clinic Proceedings*, **2015**, 90, 597-605	6.4	11
160	Release of cardiac troponin using a high sensitivity assay after exercise: Type 2 acute myocardial infarction?. *Clinica Chimica Acta*, **2015**, 446, 6-8	6.2	6
159	Reliability of Calculated Low-Density Lipoprotein Cholesterol. *American Journal of Cardiology*, **2015**, 116, 538-40	3	22
158	Soluble ST2 and galectin-3 in pediatric patients without heart failure. *Clinical Biochemistry*, **2015**, 48, 1337-40	3.5	29
157	MY APPROACH to cardiac troponin elevations in patients with renal disease. *Trends in Cardiovascular Medicine*, **2015**, 25, 655-6	6.9	
156	Sex-specific associations of established and emerging cardiac biomarkers with all-cause mortality in older adults: the ActiFE study. *Clinical Chemistry*, **2015**, 61, 389-99	5.5	29
155	Comparison of conventional and high-sensitivity troponin in patients with chest pain: a collaborative meta-analysis. *American Heart Journal*, **2015**, 169, 6-16.e6	4.9	64
154	IFCC educational materials on selected analytical and clinical applications of high sensitivity cardiac troponin assays. *Clinical Biochemistry*, **2015**, 48, 201-3	3.5	158
153	Fundamental concepts of effective troponin use: important principles for internists. *American Journal of Medicine*, **2015**, 128, 111-9	2.4	11
152	Midregional proadrenomedullin predicts mortality and major adverse cardiac events in patients presenting with chest pain: results from the CHOPIN trial. *Academic Emergency Medicine*, **2015**, 22, 554-63	3.4	10
151	Can amyotrophic lateral sclerosis chronically elevate troponin T?. *Cor Et Vasa*, **2015**, 57, e320-e322	0.3	1

150	Biochemical Validation of Patient-Reported Symptom Onset Time in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. *JACC: Cardiovascular Interventions*, **2015**, 8, 778-787	5	7
149	High-sensitivity cardiac troponin t concentrations below the limit of detection to exclude acute myocardial infarction: a prospective evaluation. *Clinical Chemistry*, **2015**, 61, 983-9	5.5	83
148	Troponin T as a Predictor of End-Stage Renal Disease and All-Cause Death in African Americans and Whites From Hypertensive Families. *Mayo Clinic Proceedings*, **2015**, 90, 1482-91	6.4	6
147	Myocardial Dysfunction in Severe Sepsis and Septic Shock: No Correlation With Inflammatory Cytokines in Real-life Clinical Setting. *Chest*, **2015**, 148, 93-102	5.3	60
146	Intervention to reduce inappropriate ionized calcium ordering practices: a quality-improvement project **2015**, 19, 49-51		9
145	Prognostic performance of high-sensitivity cardiac troponin T kinetic changes adjusted for elevated admission values and the GRACE score in an unselected emergency department population. *Clinica Chimica Acta*, **2014**, 435, 29-35	6.2	2
144	Clinical implications of the Third Universal Definition of Myocardial Infarction. *Heart*, **2014**, 100, 424-32	5.1	41
143	Republished: clinical implications of the third universal definition of myocardial infarction. *Postgraduate Medical Journal*, **2014**, 90, 502-10	2	3
142	Improving the 510(k) FDA process for cardiac troponin assays: in search of common ground. *Clinical Chemistry*, **2014**, 60, 1273-5	5.5	14
141	Men are different than women: itB true for cardiac troponin too. *Clinical Biochemistry*, **2014**, 47, 867-8	3.5	10
140	Natriuretic peptides in heart failure. *Clinical Chemistry*, **2014**, 60, 1040-6	5.5	16
139	2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Journal of the American College of Cardiology*, **2014**, 64, e139-e228	15.1	1822
138	High-sensitivity troponin I and amino-terminal pro--B-type natriuretic peptide predict heart failure and mortality in the general population. *Clinical Chemistry*, **2014**, 60, 1225-33	5.5	30
137	In search for the Holy Grail: suggestions for studies to define delta changes to diagnose or exclude acute myocardial infarction: a position paper from the study group on biomarkers of the Acute Cardiovascular Care Association. *European Heart Journal: Acute Cardiovascular Care*, **2014**, 3, 313-6	4.3	24
136	Early trends in N-terminal pro-brain natriuretic peptide values after left ventricular assist device implantation for chronic heart failure. *American Journal of Cardiology*, **2014**, 114, 1257-63	3	5
135	Nocturnal patterns of heart rate and the risk of mortality after acute myocardial infarction. *American Heart Journal*, **2014**, 168, 117-25	4.9	12
134	Canadian Institutes of Health Research dissemination grant on high-sensitivity cardiac troponin. *Clinical Biochemistry*, **2014**, 47, 155-7	3.5	4
133	High-sensitivity troponin: where are we now and where do we go from here?. *Biomarkers in Medicine*, **2014**, 8, 1021-32	2.3	5

132	Validation of a proposed novel equation for estimating LDL cholesterol. *Clinical Chemistry*, **2014**, 60, 1519-23	5.5	47
131	2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Circulation*, **2014**, 130, e344-426	16.7	754
130	Defining the optimal cardiac troponin T threshold for predicting death caused by periprocedural myocardial infarction after percutaneous coronary intervention. *Circulation: Cardiovascular Interventions*, **2014**, 7, 533-42	6	10
129	Troponin elevation in severe sepsis and septic shock: the role of left ventricular diastolic dysfunction and right ventricular dilatation*. *Critical Care Medicine*, **2014**, 42, 790-800	1.4	136
128	B-type natriuretic peptide clinical activation in aortic stenosis: impact on long-term survival. *Journal of the American College of Cardiology*, **2014**, 63, 2016-25	15.1	127
127	Clinical differences between total PAPP-A and measurements specific for the products of free PAPP-A activity in patients with stable cardiovascular disease. *Clinical Biochemistry*, **2014**, 47, 177-83	3.5	11
126	Copeptin helps in the early detection of patients with acute myocardial infarction: primary results of the CHOPIN trial (Copeptin Helps in the early detection Of Patients with acute myocardial INfarction). *Journal of the American College of Cardiology*, **2013**, 62, 150-160	15.1	127
125	Effect of population selection on 99th percentile values for a high sensitivity cardiac troponin I and T assays. *Clinical Biochemistry*, **2013**, 46, 1636-43	3.5	79
124	Preparing the United States for high-sensitivity cardiac troponin assays. *Journal of the American College of Cardiology*, **2013**, 61, 1753-8	15.1	105
123	Troponina cardiaca ultrasensible: de la teor a la pr ctica cl nica. *Revista Espanola De Cardiologia*, **2013**, 66, 687-691	1.5	22
122	Long-time quality assessment of the Elecsys Troponin T hs assay. *Clinical Biochemistry*, **2013**, 46, 1055-1057	3.5	29
121	Third universal definition of myocardial infarction. *Clinical Biochemistry*, **2013**, 46, 1-4	3.5	39
120	Documento de consenso de expertos. Tercera definici n universal del infarto de miocardio. *Revista Espanola De Cardiologia*, **2013**, 66, 132.e1-132.e15	1.5	14
119	Reply: To PMID 23395074. *Journal of the American College of Cardiology*, **2013**, 62, 648	15.1	
118	Elevated cardiac troponin T levels in critically ill patients with sepsis. *American Journal of Medicine*, **2013**, 126, 1114-21	2.4	52
117	Using high-sensitivity troponin T: the importance of the proper gold standard. *American Journal of Medicine*, **2013**, 126, 709-17	2.4	36
116	High-sensitivity cardiac troponin T in prediction and diagnosis of myocardial infarction and long-term mortality after noncardiac surgery. *American Heart Journal*, **2013**, 166, 325-332.e1	4.9	112
115	Short- and long-term individual variation in cardiac troponin in patients with stable coronary artery disease. *Clinical Chemistry*, **2013**, 59, 401-9	5.5	62

114	Defining high-sensitivity cardiac troponin concentrations in the community. *Clinical Chemistry*, **2013**, 59, 1099-107	5.5	104
113	Ninety-minute vs 3-h performance of high-sensitivity cardiac troponin assays for predicting hospitalization for acute coronary syndrome. *Clinical Chemistry*, **2013**, 59, 1407-10	5.5	21
112	Troponin--past, present, and future. *Current Problems in Cardiology*, **2012**, 37, 209-28	17.1	24
111	Troponin release--reversible or irreversible injury? Should we care?. *Clinical Chemistry*, **2012**, 58, 148-50	5.5	43
110	Prognostic value of cardiac troponin T after myocardial infarction: a contemporary community experience. *Mayo Clinic Proceedings*, **2012**, 87, 247-54	6.4	20
109	Recommendations for the use of natriuretic peptides in acute cardiac care: a position statement from the Study Group on Biomarkers in Cardiology of the ESC Working Group on Acute Cardiac Care. *European Heart Journal*, **2012**, 33, 2001-6	9.5	176
108	Diastolic dysfunction and mortality in severe sepsis and septic shock. *European Heart Journal*, **2012**, 33, 895-903	9.5	256
107	Third universal definition of myocardial infarction. *Nature Reviews Cardiology*, **2012**, 9, 620-33	14.8	146
106	How to use high-sensitivity cardiac troponins in acute cardiac care. *European Heart Journal*, **2012**, 33, 2252-7	9.5	531
105	Third universal definition of myocardial infarction. *Circulation*, **2012**, 126, 2020-35	16.7	2259
104	Interpreting biomarkers during percutaneous coronary intervention: the need to reevaluate our approach. *Archives of Internal Medicine*, **2012**, 172, 508-9		1
103	Incidence and significance of elevated lactate in the identification of critically ill patients. *Clinical Chemistry and Laboratory Medicine*, **2012**, 50, 1819-23	5.9	1
102	Why all the struggle about CK-MB and PCI?. *European Heart Journal*, **2012**, 33, 1046-8	9.5	25
101	Decision support tool for early differential diagnosis of acute lung injury and cardiogenic pulmonary edema in medical critically ill patients. *Chest*, **2012**, 141, 43-50	5.3	15
100	Cardiac Function **2012**, 1457-1522		1
99	Third universal definition of myocardial infarction. *Global Heart*, **2012**, 7, 275-95	2.9	233
98	Rapid exclusion of acute myocardial infarction in patients with undetectable troponin using a high-sensitivity assay. *Journal of the American College of Cardiology*, **2011**, 58, 1332-9	15.1	269
97	Diseased skeletal muscle: a noncardiac source of increased circulating concentrations of cardiac troponin T. *Journal of the American College of Cardiology*, **2011**, 58, 1819-24	15.1	188

96	Troponin elevations after electroconvulsive therapy: the need for caution. *American Journal of Medicine*, **2011**, 124, 229-34	2.4	10
95	Clinical implications of the change of cardiac troponin I levels in patients with acute chest pain - an evaluation with respect to the Universal Definition of Myocardial Infarction. *Clinica Chimica Acta*, **2011**, 412, 91-7	6.2	35
94	The 10 commandments of troponin, with special reference to high sensitivity assays. *Heart*, **2011**, 97, 940-6	5.1	39
93	Comparison of mass spectrometry and clinical assay measurements of circulating fragments of B-type natriuretic peptide in patients with chronic heart failure. *Circulation: Heart Failure*, **2011**, 4, 355-60	7.6	86
92	Biologic variation of a novel cardiac troponin I assay. *Clinical Chemistry*, **2011**, 57, 1080-1	5.5	28
91	Biomarkers in Acute Ischemic Heart Disease **2011**, 101-112		
90	Biochemical markers of myocardial necrosis **2011**, 125-131		
89	Biological and analytical variability of a novel high-sensitivity cardiac troponin T assay. *Clinical Chemistry*, **2010**, 56, 1086-90	5.5	125
88	Analytical validation of a high-sensitivity cardiac troponin T assay. *Clinical Chemistry*, **2010**, 56, 254-61	5.5	791
87	Being rational about (im)precision: a statement from the Biochemistry Subcommittee of the Joint European Society of Cardiology/American College of Cardiology Foundation/American Heart Association/World Heart Federation Task Force for the definition of myocardial infarction. *Clinical Chemistry*, **2010**, 56, 941-3	5.5	103
86	High-sensitivity cardiac troponin: hype, help, and reality. *Clinical Chemistry*, **2010**, 56, 342-4	5.5	33
85	Increasing cardiac troponin changes measured by a research high-sensitivity troponin I assay: absolute vs percentage changes and long-term outcomes in a chest pain cohort. *Clinical Chemistry*, **2010**, 56, 1902-4	5.5	28
84	High-sensitive cardiac troponin I (hs-cTnI) values in patients with stable cardiovascular disease: an initial foray. *Clinica Chimica Acta*, **2010**, 411, 812-7	6.2	16
83	Significance of elevated cardiac troponin T levels in critically ill patients with acute respiratory disease. *American Journal of Medicine*, **2010**, 123, 1049-58	2.4	40
82	Recommendations for the use of cardiac troponin measurement in acute cardiac care. *European Heart Journal*, **2010**, 31, 2197-204	9.5	455
81	Identification of myocardial injury in the emergency setting. *Clinical Biochemistry*, **2010**, 43, 539-44	3.5	9
80	Determinants and prognostic implications of cardiac troponin T measured by a sensitive assay in type 2 diabetes mellitus. *Cardiovascular Diabetology*, **2010**, 9, 52	8.7	29
79	Value of cardiac troponin I cutoff concentrations below the 99th percentile for clinical decision-making. *Clinical Chemistry*, **2009**, 55, 85-92	5.5	114

78	Perioperative myocardial infarction. *Circulation*, **2009**, 119, 2936-44	16.7	303
77	Refining our criteria: a critical challenge. *American Journal of Clinical Pathology*, **2009**, 131, 11-3	1.9	5
76	Screening for kidney disease in vascular patients: SCreening for Occult REnal Disease (SCORED) experience. *Nephrology Dialysis Transplantation*, **2009**, 24, 2452-7	4.3	17
75	Short- and long-term risk stratification using a next-generation, high-sensitivity research cardiac troponin I (hs-cTnI) assay in an emergency department chest pain population. *Clinical Chemistry*, **2009**, 55, 1809-15	5.5	76
74	PAPP-A as a marker of increased long-term risk in patients with chest pain. *Clinical Biochemistry*, **2009**, 42, 1012-8	3.5	25
73	Aborted myocardial infarction: is it real in the troponin era?. *American Heart Journal*, **2009**, 157, 636-41	4.9	6
72	Analytic and clinical utility of a next-generation, highly sensitive cardiac troponin I assay for early detection of myocardial injury. *Clinical Chemistry*, **2009**, 55, 573-7	5.5	140
71	History of depression and survival after acute myocardial infarction. *Psychosomatic Medicine*, **2009**, 71, 253-9	3.7	61
70	Long-term prognostic significance of elevated cardiac troponin levels in critically ill patients with acute gastrointestinal bleeding. *Critical Care Medicine*, **2009**, 37, 140-7	1.4	50
69	Depression and five year survival following acute myocardial infarction: a prospective study. *Journal of Affective Disorders*, **2008**, 109, 133-8	6.6	69
68	Cardiac magnetic resonance imaging study for quantification of infarct size comparing directly serial versus single time-point measurements of cardiac troponin T. *Journal of the American College of Cardiology*, **2008**, 51, 307-14	15.1	141
67	Weight change after myocardial infarction--the Enhancing Recovery in Coronary Heart Disease patients (ENRICHD) experience. *American Heart Journal*, **2008**, 155, 478-84	4.9	38
66	The clinical need for high-sensitivity cardiac troponin assays for acute coronary syndromes and the role for serial testing. *American Heart Journal*, **2008**, 155, 208-14	4.9	122
65	"Upstream markers" provide for early identification of patients at high risk for myocardial necrosis and adverse outcomes. *Clinica Chimica Acta*, **2008**, 387, 133-8	6.2	13
64	Development of an optimized multimarker strategy for early risk assessment of patients with acute coronary syndromes. *Clinica Chimica Acta*, **2008**, 393, 103-9	6.2	34
63	Requiem for a heavyweight: the demise of creatine kinase-MB. *Circulation*, **2008**, 118, 2200-6	16.7	83
62	Significance of periprocedural myonecrosis on outcomes after percutaneous coronary intervention: an analysis of preintervention and postintervention troponin T levels in 5487 patients. *Circulation: Cardiovascular Interventions*, **2008**, 1, 10-9	6	137
61	Cross-reactivity of BNP, NT-proBNP, and proBNP in commercial BNP and NT-proBNP assays: preliminary observations from the IFCC Committee for Standardization of Markers of Cardiac Damage. *Clinical Chemistry*, **2008**, 54, 619-21	5.5	109

60	Implications of the universal definition of myocardial infarction. *Nature Clinical Practice Cardiovascular Medicine*, **2008**, 5, 678-9		11
59	Relationship of MRI-determined infarct size and cTnI measurements in patients with ST-elevation myocardial infarction. *Clinical Chemistry*, **2008**, 54, 617-9	5.5	35
58	Key issues in the developing synergism between cardiovascular imaging and biomarkers. *Clinical Chemistry*, **2008**, 54, 1432-42	5.5	10
57	The clinical impact of the universal diagnosis of myocardial infarction. *Clinical Chemistry and Laboratory Medicine*, **2008**, 46, 1485-8	5.9	5
56	Diagnostic accuracy of clinical prediction rules to exclude acute coronary syndrome in the emergency department setting: a systematic review. *Canadian Journal of Emergency Medicine*, **2008** , 10, 373-82	0.6	55
55	Elevated cardiac troponin is an independent risk factor for short- and long-term mortality in medical intensive care unit patients. *Critical Care Medicine*, **2008**, 36, 759-65	1.4	101
54	Nighttime heart rate and survival in depressed patients post acute myocardial infarction. *Psychosomatic Medicine*, **2008**, 70, 757-63	3.7	8
53	Usefulness of detectable levels of troponin, below the 99th percentile of the normal range, as a clue to the presence of underlying coronary artery disease. *American Journal of Cardiology*, **2007**, 100, 764-9	3	45
52	National Academy of Clinical Biochemistry laboratory medicine practice guidelines: use of cardiac troponin and B-type natriuretic peptide or N-terminal proB-type natriuretic peptide for etiologies other than acute coronary syndromes and heart failure. *Clinical Chemistry*, **2007**, 53, 2086-96	5.5	201
51	Myocardial infarction with normal coronary arteries: a role for MRI?. *Clinical Chemistry*, **2007**, 53, 995-6	5.5	17
50	National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine Practice Guidelines: analytical issues for biochemical markers of acute coronary syndromes. *Clinical Chemistry*, **2007**, 53, 547-51	5.5	168
49	Regional systems of care to optimize timeliness of reperfusion therapy for ST-elevation myocardial infarction: the Mayo Clinic STEMI Protocol. *Circulation*, **2007**, 116, 729-36	16.7	260
48	B-type natriuretic peptides in heart failure: update on clinical applications and limitations. *Biomarkers in Medicine*, **2007**, 1, 503-12	2.3	2
47	Serial biomarker measurements in ambulatory patients with chronic heart failure: the importance of change over time. *Circulation*, **2007**, 116, 249-57	16.7	141
46	Universal definition of myocardial infarction. *Circulation*, **2007**, 116, 2634-53	16.7	1953
45	Long-term health outcomes associated with detectable troponin I concentrations. *Clinical Chemistry*, **2007**, 53, 220-7	5.5	56
44	Social support and prognosis in patients at increased psychosocial risk recovering from myocardial infarction. *Health Psychology*, **2007**, 26, 418-27	5	92
43	Heart rate turbulence, depression, and survival after acute myocardial infarction. *Psychosomatic Medicine*, **2007**, 69, 4-9	3.7	37

42	Cardiovascular biomarkers: the state of the art in 2006. *Clinica Chimica Acta*, **2007**, 381, 9-13	6.2	20
41	Multi-center validation of the Response Biomedical Corporation RAMP NT-proBNP assay with comparison to the Roche Diagnostics GmbH Elecsys proBNP assay. *Clinica Chimica Acta*, **2007**, 386, 20-4	6.2	20
40	The use of biomarkers for the evaluation and treatment of patients with acute coronary syndromes. *Medical Clinics of North America*, **2007**, 91, 657-81; xi	7	20
39	Lipoprotein-associated phospholipase A2 and prognosis after myocardial infarction in the community. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2006**, 26, 2517-22	9.4	74
38	Redefinition of myocardial infarction: prospective evaluation in the community. *Circulation*, **2006**, 114, 790-7	16.7	122
37	Health outcomes categorized by current and previous definitions of acute myocardial infarction in an unselected cohort of troponin-naïve emergency department patients. *Clinical Chemistry*, **2006**, 52, 2028-35	5.5	21
36	Importance of low concentrations of cardiac troponins. *Clinical Chemistry*, **2006**, 52, 1614-5	5.5	31
35	Assessing the requirement for the 6-hour interval between specimens in the American Heart Association Classification of Myocardial Infarction in Epidemiology and Clinical Research Studies. *Clinical Chemistry*, **2006**, 52, 812-8	5.5	151
34	Baseline troponin level: key to understanding the importance of post-PCI troponin elevations. *European Heart Journal*, **2006**, 27, 1061-9	9.5	107
33	Brain natriuretic peptide levels in constrictive pericarditis and restrictive cardiomyopathy. *Journal of the American College of Cardiology*, **2006**, 47, 1489-91	15.1	49
32	Biomarkers in acute cardiac disease: the present and the future. *Journal of the American College of Cardiology*, **2006**, 48, 1-11	15.1	1092
31	Prediction of medical morbidity and mortality after acute myocardial infarction in patients at increased psychosocial risk in the Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD) study. *American Heart Journal*, **2006**, 152, 126-35	4.9	63
30	Lipoprotein-associated phospholipase A2: review and recommendation of a clinical cut point for adults. *Preventive Cardiology*, **2006**, 9, 138-43		36
29	Elevations of troponin in patients with epileptic seizures? What do they mean?. *Clinical Cardiology*, **2006**, 29, 325-6	3.3	15
28	Biomarker responses during and after treatment with nesiritide infusion in patients with decompensated chronic heart failure. *Clinical Chemistry*, **2005**, 51, 569-77	5.5	39
27	Use of biomarkers in the emergency department and chest pain unit. *Cardiology Clinics*, **2005**, 23, 453-65, vi	2.5	10
26	Validation of the 99th percentile cutoff independent of assay imprecision (CV) for cardiac troponin monitoring for ruling out myocardial infarction. *Clinical Chemistry*, **2005**, 51, 2198-200	5.5	102
25	Lower rather than higher levels of B-type natriuretic peptides (NT-pro-BNP and BNP) predict short-term mortality in end-stage heart failure patients treated with nesiritide. *American Journal of Cardiology*, **2005**, 96, 837-41	3	38

24	Effects of antidepressant medication on morbidity and mortality in depressed patients after myocardial infarction. *Archives of General Psychiatry*, **2005**, 62, 792-8		398
23	Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome. *Clinical Chemistry*, **2005**, 51, 810-24	5.5	340
22	Quality specifications for B-type natriuretic peptide assays. *Clinical Chemistry*, **2005**, 51, 486-93	5.5	161
21	Troponin: the biomarker of choice for the detection of cardiac injury. *Cmaj*, **2005**, 173, 1191-202	3.5	409
20	Practical implementation of the guidelines for unstable angina/non-ST-segment elevation myocardial infarction in the emergency department: a scientific statement from the American Heart Association Council on Clinical Cardiology (Subcommittee on Acute Cardiac Care), Council on Cardiovascular Nursing, and Quality of Care and Outcomes Research Interdisciplinary Working	16.7	95
19	Can creatine kinase MB levels predict mortality after cardiac surgery? *Nature Clinical Practice Cardiovascular Medicine*, **2005**, 2, 280-1		1
18	Clinical characteristics and thrombolysis in myocardial infarction frame counts in women with transient left ventricular apical ballooning syndrome. *American Journal of Cardiology*, **2004**, 94, 343-6	3	462
17	Timing of peak troponin T and creatine kinase-MB elevations after percutaneous coronary intervention. *Chest*, **2004**, 125, 275-80	5.3	46
16	Case definitions for acute coronary heart disease in epidemiology and clinical research studies: a statement from the AHA Council on Epidemiology and Prevention; AHA Statistics Committee; World Heart Federation Council on Epidemiology and Prevention; the European Society of Cardiology Working Group on Epidemiology and Prevention; Centers for Disease Control and Prevention; and the National Heart, Lung, and Blood Institute. *Circulation*, **2003**, 108, 2543-9	16.7	632
15	Effect of myocardial ischemia on cardiac troponin I and T. *American Journal of Cardiology*, **2002**, 89, 224-6	3	22
14	Elevations of cardiac troponin I are associated with increased short-term mortality in noncardiac critically ill emergency department patients. *American Journal of Cardiology*, **2002**, 90, 634-6	3	56
13	Long-term prognosis of patients with clinical unstable angina pectoris without elevation of creatine kinase but with elevation of cardiac troponin i levels. *American Journal of Cardiology*, **2002**, 90, 875-8	3	23
12	Acute myocardial infarction and renal dysfunction: a high-risk combination. *Annals of Internal Medicine*, **2002**, 137, 563-70	8	425
11	European Society of Cardiology and American College of Cardiology guidelines for redefinition of myocardial infarction: how to use existing assays clinically and for clinical trials. *American Heart Journal*, **2002**, 144, 981-6	4.9	336
10	Elevations in cardiac troponin measurements: false false-positives: the real truth. *Cardiovascular Toxicology*, **2001**, 1, 87-92	3.4	56
9	Bedside Multimarker Testing for Risk Stratification in Chest Pain Units: The Chest Pain Evaluation by Creatine Kinase-MB, Myoglobin, and Troponin I (CHECKMATE) Study. *Circulation*, **2001**, 104,	16.7	8
8	Cardiac involvement in patients with acute neurologic disease: confirmation with cardiac troponin I. *Archives of Internal Medicine*, **2000**, 160, 3153-8		58
7	The costs of inadequate data. *Academic Emergency Medicine*, **2000**, 7, 687-8	3.4	

6	Elevated cardiac troponin levels predict the risk of adverse outcome in patients with acute coronary syndromes. *American Heart Journal*, **2000**, 140, 917-27	4.9	197
5	Prognostic influence of elevated values of cardiac troponin I in patients with unstable angina. *Circulation*, **1997**, 95, 2053-9	16.7	224
4	Diagnosis of perioperative myocardial infarction with measurement of cardiac troponin I. *New England Journal of Medicine*, **1994**, 330, 670-4	59.2	466
3	Recommended guidelines for in-hospital cardiac monitoring of adults for detection of arrhythmia. Emergency Cardiac Care Committee members. *Journal of the American College of Cardiology*, **1991**, 18, 1431-3	15.1	64
2	Major depressive disorder in coronary artery disease. *American Journal of Cardiology*, **1987**, 60, 1273-5	3	296
1	Global Adoption of High-Sensitivity Cardiac Troponins and the Universal Definition of Myocardial Infarction		1